Immix Biopharma will host investor meetings at the Jefferies Global Healthcare Conference, showcasing its advancements in AL Amyloidosis treatment.
Quiver AI Summary
Immix Biopharma, Inc. announced its participation in the Jefferies Global Healthcare Conference, scheduled for June 2-4, 2026, in New York, where the company will host institutional investor meetings and offer one-on-one discussions. ImmixBio is positioned as a leader in treating relapsed/refractory AL Amyloidosis, a severe condition caused by toxic light chains affecting vital organs. The company’s leading therapy candidate, NXC-201, is a CAR-T cell therapy designed to target and eliminate these toxic chains and is currently under evaluation in a pivotal study. NXC-201 has received significant designations from the FDA, including Breakthrough Therapy and Regenerative Medicine Advanced Therapy. Investors interested in scheduling meetings can contact their Jefferies representative.
Potential Positives
- Immix Biopharma is participating in a prestigious investor conference, which enhances visibility and credibility within the healthcare investment community.
- The company’s lead candidate, NXC-201, has received multiple significant designations including Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy, indicating strong potential in the treatment of AL Amyloidosis.
- Immix Biopharma is recognized as the global leader in the treatment of relapsed/refractory AL Amyloidosis, positioning the company strongly in a niche market with substantial unmet needs.
Potential Negatives
- Participation in the Jefferies Global Healthcare Conference suggests a need for external validation and investor interest, potentially indicating that the company is seeking to bolster its market presence amidst competitive pressures.
- The reliance on the performance of NXC-201 in a registrational study highlights the company's dependence on a single product, which could pose a significant risk if clinical outcomes are not favorable.
- Despite having received Breakthrough Therapy Designation and other recognitions, the inclusion of alarming statistics about AL Amyloidosis raises concerns regarding the severity of the condition and pressures on the company to deliver effective solutions rapidly.
FAQ
What is Immix Biopharma, Inc. known for?
Immix Biopharma, Inc. is the global leader in relapsed/refractory AL Amyloidosis treatment.
When is the Jefferies Global Healthcare Conference?
The Jefferies Global Healthcare Conference will be held from June 2-4, 2026.
How can investors request meetings during the conference?
Interested investors should contact their Jefferies representative to request one-on-one meetings.
What is the lead therapy being developed by ImmixBio?
ImmixBio's lead therapy is NXC-201, a CAR-T cell therapy targeting AL Amyloidosis.
What designations has NXC-201 received from the FDA?
NXC-201 has received Breakthrough Therapy Designation, RMAT, and Orphan Drug Designation from the FDA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMMX Insider Trading Activity
$IMMX insiders have traded $IMMX stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMMX stock by insiders over the last 6 months:
- GABRIEL S MORRIS (CFO) purchased 770 shares for an estimated $5,066
- ILYA M RACHMAN (CEO and Chairman) purchased 746 shares for an estimated $4,975
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IMMX Hedge Fund Activity
We have seen 57 institutional investors add shares of $IMMX stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 3,921,568 shares (+inf%) to their portfolio in Q4 2025, for an estimated $20,509,800
- SATURN V CAPITAL MANAGEMENT LP added 2,999,169 shares (+inf%) to their portfolio in Q4 2025, for an estimated $15,685,653
- EVENTIDE ASSET MANAGEMENT, LLC added 2,549,019 shares (+inf%) to their portfolio in Q4 2025, for an estimated $13,331,369
- MARSHALL WACE, LLP added 1,923,708 shares (+3495.4%) to their portfolio in Q4 2025, for an estimated $10,060,992
- MILLENNIUM MANAGEMENT LLC added 1,659,778 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,680,638
- LOGOS GLOBAL MANAGEMENT LP added 1,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,230,000
- BLUE OWL CAPITAL HOLDINGS LP added 986,240 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,158,035
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMMX Price Targets
Multiple analysts have issued price targets for $IMMX recently. We have seen 5 analysts offer price targets for $IMMX in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Graig Suvannavejh from Mizuho set a target price of $15.0 on 03/30/2026
- Robert Burns from HC Wainwright & Co. set a target price of $15.0 on 03/30/2026
- Reni J. Benjamin from Citizens set a target price of $23.0 on 03/27/2026
- Judah Frommer from Morgan Stanley set a target price of $20.0 on 03/25/2026
Full Release
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contacts
Mike Moyer
LifeSci Advisors
[email protected]
Company Contact
[email protected]
